Forum Topic News
  • Conversation: US priority review for Keytruda/chemo combo in first-line squamous NSCLC

    • July 3, 2018 12:56 PM BST
    • US priority review for Keytruda/chemo combo in first-line squamous NSCLC

      US regulators have assigned a priority review to MSD’s application to market the immunotherapy Keytruda in combination with chemotherapy as a first-line treatment for squamous non-small cell lung cancer (NSCLC).
      The application is based on data from the Phase III KEYNOTE-407 trial, in which Keytruda (pembrolizumab) plus chemotherapy cut the risk of death by 36 percent compared to chemotherapy alone, when used as a first-line treatment for patients with metastatic squamous NSCLC.
      The addition of Keytruda to chemotherapy also significantly improved progression-free survival (PFS), with a reduction in the risk of disease progression or death of 44 percent, according to the results.
      Read more: http://www.pharmatimes.com/news/us_priority_review_for_keytrudachemo_combo_in_first-line_squamous_nsclc_1243027

Add Reputation

Do you want to add reputation for this member by this post?

or cancel